Moreover, we identified the case subjects in a strict accordance with a generally accepted definition of CAD and excluded patients taking niacin which could decrease the plasma level of Lp(a) and/or patients with diabetes since diabetes status was reported to attenuate the relation between Lp(a) and cardiovascular risk [17]. The gene discussed is LPA; the disease is coronary artery disorder.